Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 356

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 356
---
 Coupling the acoustic energy of transcranial ultrasound (“TUS”) with tPA has been shown in clinical studies
to significantly increase restoration of blood flow in stroke patients. Ultrasound generates acoustic streaming
at the site of the blood clot, which causes tPA to be refreshed at the surface of the occlusion, resulting in an increased rate of clot
dissolution. Ultrasound is also known to reversibly disaggregate fibrin strands within the clot, specifically making the strands longer
and thinner, which exposes additional binding sites on the fibrin for conversion of plasminogen to plasmin to aid in clot lysis.

| 7 | Seners P. Turc G, Naggara O, Henon H, Piotin M, Arquizan C, Cho TH, Narata AP, Lapergue B, Richard S, 
 et al. (2018). Post-Thrombolysis Recanalization in Stroke Referrals for Thrombectomy.                 |

| 187 |

The Aureva
Pulse is non-invasive and is designed to be easily administered in the emergency room environment once the stroke diagnosis has been confirmed
and tPA administered. The device is designed to be portable and to travel with stroke patients that are determined to be viable candidates
to undergo transport to a comprehensive stroke center for thrombectomy. Increasing the rate of vessel recanalization in patients that
do not have immediate access to thrombectomy services may directly address this current treatment gap in stroke care.

The Aureva
Pulse is comprised of three major components: The headset, transducer with connecting cable, and the control box. It is designed to be
an operator independent system. Once the headset is placed on the subject’s head and the ultrasound therapy is activated, the system
will provide the therapy independent of the need for a trained ultrasonographer to aim or hold the transducer in place. To administer
TUS, the headset of the device utilizes a single re-locatable transducer array that is inserted into an adjustable headset at one of two
locations (right temporal or left temporal) based on confirmed clot location from pre- treatment CT angiography (“CTA”). The
transducer array positions are fixed in place to take advantage of the known acoustic windows on the human head, specifically the two
temporal windows. Through these windows, the device administers TUS to the principal regions in which large vessel occlusions of the cerebral
vasculature are generally known to occur,